Trial for new diabetes duo withdrawn before starting
NCT ID NCT07172867
Summary
This study aimed to see if adding a new drug called ofirnoflast to the existing medication semaglutide (like Ozempic®) was better for blood sugar control and weight loss in adults with type 2 diabetes who were overweight or obese. It was designed as a 12-week trial comparing the combination to semaglutide alone. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Abu Dhabi
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Conditions
Explore the condition pages connected to this study.